✦ LIBER ✦

Nuclear regulatory proteins may modify endocrine therapy in breast cancer

✍ Scribed by F. J. Fleming; A. D. K. Hill; E. W. McDermott; N. O’Higgins; L. S. Young

Publisher: Springer-Verlag
Year: 2002
Tongue: English
Weight: 218 KB
Volume: 171
Category: Article
ISSN: 1863-4362
DOI: 10.1007/bf03170249

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma changes in breast cancer patients

Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

✍ Terje Engan; Jostein Krane; Dag C. Johannessen; Per E. Lønning; Stener Kvinnslan 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 784 KB

Immunocytochemical localization of fos p

Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

✍ Julia M. W. Gee; Ian O. Ellis; John F. R. Robertson; Peter Willsher; Richard A. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 805 KB

The nuclear transcription factor Fos is inducible by both steroid hormones and peptide growth factors. It thus forms a potential point of interaction between steroid hormone-and growth factor-directed pathways and may be critical in the subversion of steroid hormone control in breast cancer. In this

Immunocytochemical localization of BCL-2

Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

✍ Julia M. W. Gee; John F. R. Robertson; Ian O. Ellis; Peter Willsher; Richard A. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 824 KB

The protein product of the bcl-2 gene is thought to be involved in inhibition of apoptosis; it may therefore be important in the modulation of hormonal/anti-hormonal responsiveness exhibited by tumours. This study immunocytochemically investigates (i) relationships between bcl-2 protein expression i